België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sanofi belgium sa-nv - inosine pranobex 500 mg - tablet - 500 mg - inosine pranobex 500 mg - inosine pranobex

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

johnson & johnson consumer sa-nv - cetirizinedihydrochloride 5 mg; pseudo-efedrinehydrochloride 120 mg - tablet met verlengde afgifte - 5 mg - 120 mg - cetirizinedihydrochloride 5 mg; pseudo-efedrinehydrochloride 120 mg - pseudoephedrine, combinations

Europese Unie - Nederlands - EMA (European Medicines Agency)

glaxosmithkline trading services - mepolizumab - astma - geneesmiddelen voor obstructieve aandoeningen van de luchtwegen, - severe eosinophilic asthmanucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. chronic rhinosinusitis with nasal polyps (crswnp)nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. eosinophilic granulomatosis with polyangiitis (egpa)nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (egpa). hypereosinophilic syndrome (hes)nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.

Europese Unie - Nederlands - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - middelen voor dermatitis, met uitzondering van corticosteroïden - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Europese Unie - Nederlands - EMA (European Medicines Agency)

novartis europharm limited - omalizumab - asthma; urticaria - geneesmiddelen voor obstructieve aandoeningen van de luchtwegen, - allergische asthmaxolair is geïndiceerd bij volwassenen, adolescenten en kinderen (6 tot.

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

teva b.v. - azathioprine natrium samenstelling overeenkomend met; azathioprine; - poeder voor oplossing voor injectie - azathioprine

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

johnson & johnson consumer sa-nv - ibuprofen 200 mg; pseudo-efedrinehydrochloride 30 mg - filmomhulde tablet - 200 mg - 30 mg - ibuprofen 200 mg; pseudo-efedrinehydrochloride 30 mg - other cold preparations

Europese Unie - Nederlands - EMA (European Medicines Agency)

passauer pharma gmbh - mycofenolaat mofetil - graft rejection - immunosuppressiva - myclausen is geïndiceerd in combinatie met ciclosporine en corticosteroïden voor de profylaxe van acute transplantaatafstoting bij patiënten die allogene nier-, hart- of levertransplantaties ontvangen..

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

eureco-pharma b.v. boelewerf 2 2987 vd ridderkerk - metamizol natrium 1-water samenstelling overeenkomend met ; metamizol - oplossing voor injectie - water voor injectie, - metamizole sodium

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

eureco-pharma b.v. boelewerf 2 2987 vd ridderkerk - metamizol natrium 1-water 500 mg/ml samenstelling overeenkomend met ; metamizol 443 mg/ml - oplossing voor injectie - water voor injectie ; zwavelzuur (e 513), - metamizole sodium